2 assets in Pseudomyxoma Peritonei

Therapeutic assets addressing Pseudomyxoma Peritonei, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Pseudomyxoma Peritonei	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Pseudomyxoma Peritonei	National Cancer Institute (NCI)	P2	CCC (53)